Bosh sahifaMLLCF • OTCMKTS
add
Molecular Partners AG
Yopilish kursi
4,22 $
Yillik diapazon
4,00 $ - 10,14 $
Bozor kapitalizatsiyasi
152,36 mln USD
Narx/foyda
-
Dividend daromadliligi
-
Asosiy maydon
SWX
Yangiliklarda
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
| (CHF) | mar, 2025info | Y/Y qiyosi |
|---|---|---|
Daromad | — | — |
Joriy xarajat | 16,14 mln | 259,35% |
Sof foyda | -16,77 mln | -48,09% |
Sof foyda marjasi | — | — |
Har bir ulushga tushum | -0,45 | — |
EBITDA | -15,59 mln | -2,21% |
Amaldagi soliq stavkasi | 0,01% | — |
Balans
Jami aktivlari
Jami passivlari
| (CHF) | mar, 2025info | Y/Y qiyosi |
|---|---|---|
Naqd pul va qisqa investitsiyalar | 130,91 mln | -24,82% |
Jami aktivlari | 141,10 mln | -23,98% |
Jami passivlari | 12,90 mln | -24,36% |
Umumiy kapital | 128,19 mln | — |
Tarqatilgan aksiyalar | 37,27 mln | — |
Narxi/balansdagi bahosi | 1,23 | — |
Aktivlardan daromad | -26,94% | — |
Kapitaldan daromad | -29,41% | — |
Pul aylanmasi
Naqd pulning sof oʻzgarishi
| (CHF) | mar, 2025info | Y/Y qiyosi |
|---|---|---|
Sof foyda | -16,77 mln | -48,09% |
Operatsiyalardan naqd pul | -17,08 mln | -0,18% |
Sarmoyadan naqd pul | 34,96 mln | 98,53% |
Moliyadan naqd pul | -302,00 ming | -0,67% |
Naqd pulning sof oʻzgarishi | 17,50 mln | 1 588,90% |
Boʻsh pul | -13,72 mln | -22,38% |
Haqida
Molecular Partners AG is a clinical-stage biopharmaceutical company based in Zürich, Switzerland. The company is developing a new class of potent, specific and versatile small-protein therapies called DARPins, with potential clinical applications in a range of disease areas including oncology, immuno-oncology, ophthalmology, and infectious diseases. Molecular Partners currently has two DARPin molecules in clinical development, and a broad pipeline of molecules in preclinical development. Wikipedia
Tashkil etilgan
2004
Xodimlar soni
159
